PainQx is a diagnostic/software company based in New York and Philadelphia that has developed an objective method to measure chronic and acute pain in humans. Its platform assesses neural activity from a patient’s brain and processes and decodes the data through proprietary algorithms to produce a scaled pain and neurological side‑effects biomarker correlated to a patient’s pain state. The system is currently used as a clinical assessment tool by companies using pain as a primary or secondary clinical endpoint to measure drug or device efficacy. Following FDA clearance, PainQx plans to enter the broader physicians market to help practitioners diagnose and treat chronic pain more effectively. The company positions its technology as a way to improve dosing, monitor treatment effectiveness, and help address challenges posed by the opioid epidemic. Mid Atlantic Bio Angels has invested in the company, which management says will provide both financial support and domain expertise. PainQx is a Philadelphia startup developing software that uses EEG headsets and brain‑mapping to objectively measure patient pain. The technology is licensed from the NYU School of Medicine. The company sees EEG as the most scalable approach to capture pain‑related electrical activity and aims to change the standard of care for pain assessment. PainQx plans an incremental validation path starting with CROs and pharmaceutical pain‑management clinical trials, then moving into nursing homes and assisted‑living settings for nonverbal patients. The device is positioned to reduce trial costs, improve patient selection and outcome data, and support payor/provider quality measures. PainQx has raised about $1.3 million so far and is seeking additional financing to advance validation and commercialization.

Total raised

$0M

Funding rounds

2

Latest round

Equity

Latest activity

Jun 2015